Work

Phase 1/2 Study of Ap26113 in Patients (PTS) with Advanced Malignancies, Including Anaplastic Lymphoma Kinase (ALK)–Positive Non-Small Cell Lung Cancer (NSCLC): Analysis of Safety and Efficacy at Selected Phase 2 Doses

Year: 2015

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdv050.03

Authors: R. Rosell, S. Gettinger, L.A. Bazhenova, C.J. Langer, R. Salgia, K. Gold, A.T. Shaw, D.J. Dorer, D. Kerstein, D.R. Camidge

Institutions: Institut Català d'Oncologia, Yale University, University of California San Diego, Moores Cancer Center, Abramson Cancer Center, University of Pennsylvania, University of Chicago, University of Chicago Medical Center, The University of Texas MD Anderson Cancer Center, Harvard University, Massachusetts General Hospital, ARIAD Pharmaceuticals (United States), University of Colorado Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2320076767

FWCI:

Cites:

Cited by: 1

Related to: 10